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Original article

Prognosis is worse with elevated cardiac troponin in
nonacute coronary syndrome compared with acute coronary
syndrome

Yu Horiuchia,b, Nicholas Wetterstena, Mitul P. Patela,
Christian Muellerc, Sean-Xavier Neathd, Robert H. Christensone,
Nils G. Morgenthalerf, James McCordg, Richard M. Nowakh,
Gary M. Vilked, Lori B. Danielsa, Judd E. Hollanderi, Fred S. Applej,
Chad M. Cannonk, John T. Nagurneyl, Donald Schreiberm,
Christopher deFilippin, Christopher Hogano, Deborah B. Diercksp,
Gary Headdenq, Alexander T. Limkakeng Jr.r, Inder Anands, Alan H.B. Wut,
Stefan Ebmeyeru, Allan S. Jaffev, W. Frank Peacockw and Alan Maisela
Background Cardiac troponin (cTn) can be elevated in
many patients presenting to the emergency department
(ED) with chest pain but without a diagnosis of acute
coronary syndrome (ACS). We compared the prognostic
significance of cTn in these different populations.

Conclusion In patients presenting to the ED with
chest pain, cTnI elevation was associated with a worse
prognosis in non-ACS patients than in ACS patients. Coron
Artery Dis 33: 376–384 Copyright © 2022 Wolters Kluwer
Health, Inc. All rights reserved.

Methods We retrospectively analyzed the CHOPIN
study, which enrolled patients who presented to the ED
with chest pain. Patients were grouped as ACS, nonACS cardiovascular disease, noncardiac chest pain and
chest pain not otherwise specified (NOS). We examined
the prognostic ability of cTnI for the clinical endpoints of
mortality and major adverse cardiovascular event (MACE;
a composite of acute myocardial infarction, unstable
angina, revascularization, reinfarction, and congestive
heart failure and stroke) at 180-day follow-up.

Coronary Artery Disease 2022, 33:376–384

Results Among 1982 patients analyzed, 14% had ACS, 21%
had non-ACS cardiovascular disease, 31% had a noncardiac
diagnosis and 34% had chest pain NOS. cTnI elevation
above the 99th percentile was observed in 52, 18, 6 and 7%
in these groups, respectively. cTnI elevation was associated
with mortality and MACE, and their relationships were more
prominent in noncardiac diagnosis and chest pain NOS than in
ACS and non-ACS cardiovascular diagnoses for mortality, and
in non-ACS patients than in ACS patients for MACE (hazard
ratio for doubling of cTnI 1.85, 2.05, 8.26 and 4.14, respectively;
P for interaction 0.011 for mortality; 1.04, 1.23, 1.54 and 1.42,
respectively; P for interaction <0.001 for MACE).
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Introduction

Cardiac troponin (cTn) is an established biomarker of
myocardial damage, and detecting an elevated cTn is
Supplemental Digital Content is available for this article. Direct URL citations
appear in the printed text and are provided in the HTML and PDF versions of this
article on the journal's website, www.coronary-artery.com.
0954-6928 Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

a significant clinical branch point for diagnosing acute
myocardial infarction (AMI) [1]. However, cTn elevations often are observed in individuals without acute coronary syndrome (ACS), and these have been repeatedly
reported to predict future cardiovascular events and a
worse prognosis [2–5]. Nevertheless, some clinicians only
DOI: 10.1097/MCA.0000000000001135
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consider cTn for its utility in the diagnosis of AMI and do
not appreciate the clinical significance of an elevated cTn
in other clinical situations. After the diagnosis of AMI has
been ruled out, causes of cTn elevation and treatment for
myocardial injury are infrequently considered, implying
the prognostic implication of cTn in non-ACS patients is
underestimated compared with that in ACS [6–8].
The CHOPIN (Copeptin Helps in the early detection
Of Patients with acute myocardial INfarction) study was
a prospective, multicentre, international cohort study
enrolling patients who presented to the Emergency
Department (ED) with chest pain or ischemic equivalent symptoms [9]. In this post hoc analysis, we aimed
to investigate the prevalence and prognostic implication
of cTnI elevations above the 99th percentile in patients
with ACS, cardiovascular disease but non-ACS, noncardiac diseases and chest pain not otherwise specified
(NOS), and whether the prognostic significance of cTnI
is different between these populations.

Methods

The CHOPIN study was a prospective, multicentre, international cohort study enrolling patients who presented
to ED with chest pain or ischemic equivalent symptoms
within 6 h of symptom onset between September 2009
and October 2010 [9]. Patients with symptoms that were
clearly not related to ACS were excluded. The study was
conducted in accordance with International Conference
On Harmonization/Good Clinical Practice regulations
and with local IRB approval at all sites, and all patients
provided written informed consent for participation.
Patients were seen and evaluated in the ED of the participating trial sites by emergency physicians who performed their usual standard of care assessment and
treatment. Local-site troponin values were used to guide
patient management. In addition, blood samples were
obtained at the time of presentation (0 h) and then 2,
6, 24 and 72 h later if the patient was still hospitalized.
The blood was centrifuged, and plasma was stored at
−60 ℃ for analysis later in the study core laboratory. cTnI
was measured with the cTnI Ultra assay on an ADVIA
Centaur XP system (Siemens Healthcare Diagnostics,
Norwood, Massachusetts, USA). The assay detection
limit was 6 ng/l, measuring range was 6–50 ng/l, the 99th
percentile was 40 ng/l and 10% coefficient of variation
was 30 ng/l. Results of Centaur analysis were not available to the treating physician. According to consensus
recommendations, a diagnostically relevant rise or fall in
cTnI was defined as a change >20% [10].
After the completion of a 30-day follow-up, each case
report form was reviewed by at least two board-certificated cardiologists at each institution, who separately
determined the final diagnosis for initial presenting
symptoms. In the event of disagreement between reviewers, a third reviewer adjudicated the case. cTn and cutoff
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values were based on the local study site assay and were
used by the adjudicating physician for the determination
of the final diagnosis. All final diagnoses were assigned
to one of the following categories: (a) ACS [either AMI
or unstable angina (UA)]; (b) cardiovascular disease but
non-ACS etiology; (c) noncardiac diagnosis and (d) chest
pain NOS. A cardiovascular disease but non-ACS etiology included chronic stable angina, aortic valve stenosis,
aortic dissection, congestive heart failure (CHF), hypertensive crisis, perimyocarditis, syncope, ventricular tachycardia, atrial fibrillation, other arrhythmias, Takotsubo
cardiomyopathy, other specific diagnoses, and symptoms known to be non-ACS but no evidence for specific
diagnosis. Noncardiac diagnoses included pulmonary
embolism, chronic obstructive pulmonary disease exacerbation, dehydration, pneumonia, nonpneumonia infection, influenza/viral infection, renal failure, stroke, other
specific noncardiac diagnoses, and symptoms known to
be noncardiac but no evidence for the specific diagnosis.
The primary endpoints were all-cause mortality and
major adverse cardiovascular events (MACE) within
6 months after initial presentation. MACE was defined
as ED visit or hospitalization for the following diagnoses:
AMI, UA, revascularization, reinfarction, CHF and stroke.
Secondary endpoints were ischemic events (AMI, UA,
revascularization and reinfarction), and CHF assessed
individually. Patients were followed up via telephone or
medical records for the endpoints within the follow-up
time frames of 30, 90 and 180 days.
Analysis of variance, Kruskal–Wallis and Chi-square tests
were used as appropriate to compare the patient characteristics between different diagnoses. Kaplan–Meier
analysis, log-rank test and Cox analysis were used for
mortality and MACE analyses. cTnI was evaluated as a
continuous variable with log-2 transformation and as a
categorical variable with cutoff of 99th percentile. cTnI
was also classified as no elevation above the 99th percentile, acute elevation and chronic elevation [1]. An
acute troponin elevation was defined as a rise or fall of
cTnI with at least one value above the 99th percentile
[1]. Troponin elevation above the 99th percentile but
without a rise/fall was defined as a chronic elevation. An
interaction between the final diagnosis and cTnI for mortality and MACE was evaluated. Multivariable analysis
was not performed for mortality because of a small number of events. In multivariable analysis for MACE, age
and sex were included in the model, and other possible
confounders were included when a P-value <0.10 in univariable analysis. All statistical analyses were performed
using R x64 3.6.3 for Windows.

Results

Among 2071 patients recruited, six presented >6 h after
symptom onset, eight lacked a final diagnosis and 18 had
missing admission cTnI values and thus were excluded,

Copyright © 2022 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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leaving 1982 patients included in this analysis. The final
adjudicated diagnosis was ACS in 287 (14%), non-ACS
cardiovascular disease in 418 (21%), noncardiac diagnosis
in 608 (31%) and chest pain NOS in 669 patients (34%).
The number of detailed finals diagnoses is shown in
Supplementary Table 1, supplemental digital content 1,
http://links.lww.com/MCA/A485.
Patients with ACS and non-ACS cardiovascular diagnoses were older, more frequently male and Caucasian
(Table 1). They more often had a history of cardiovascular diseases and risk factors, except current smoking that
was more frequently observed in those with a noncardiac
diagnosis and chest pain NOS. Non-ACS cardiovascular
patients most frequently had a history of CHF and atrial
fibrillation. Patients with ACS and non-ACS cardiovascular diagnoses were more commonly treated with cardiovascular medications prior to presentation, and warfarin
was most often prescribed in non-ACS cardiovascular disease. At presentation to the ED, systolic blood pressure,
creatinine and natriuretic peptides were higher in those
with ACS and non-ACS cardiovascular diagnoses.
On presentation to the ED, patients with ACS had the
highest cTnI concentrations and those with non-ACS
Table 1

cardiovascular diseases had the second-highest cTnI
(median cTnI levels; 44 ng/l in ACS, 8 ng/l in non-ACS
cardiovascular, 6 ng/l in noncardiac diagnosis and 6 ng/l in
chest pain NOS, P < 0.001). An acute cTnI elevation was
observed in 57% of ACS, 15% of non-ACS cardiovascular
diagnosis and 6% of noncardiac diagnosis and chest pain
NOS (Fig. 1). A chronic cTnI elevation was observed in
9, 9, 3 and 4%, respectively.
During the initial investigation, stress testing, coronary
angiography, percutaneous coronary intervention (PCI)
and coronary artery bypass grafting (CABG) were performed in 30, 19, 7.1 and 1.3%, respectively. Those with
ACS most frequently underwent coronary angiography
than those with other diagnoses (72% in ACS, 16% in
non-ACS cardiovascular, 10% in noncardiac and 5% in
chest pain NOS, P < 0.001, Supplementary Fig. 1, supplemental digital content 1, http://links.lww.com/MCA/
A485). Stress testing was more frequently performed
in those with non-ACS (19% in ACS, 38% in non-ACS
cardiovascular, 33% in noncardiac and 28% in chest pain
NOS, P < 0.001). PCI and CABG were mainly performed
in those with ACS (PCI: 45% in ACS, 1% in non-ACS
cardiovascular and noncardiac and 0% in chest pain
NOS, P < 0.001; CABG: 8% in ACS, 1% in non-ACS

Baseline characteristics

Variables
Demographics
Age, [mean (SD)]*
Sex, male (%)*
Caucasian, number (%)*
Past medical history
CAD, number (%)*
Hypertension, number (%)*
Heart failure, number (%)*
Dyslipidemia, number (%)*
Stroke, number (%)*
Diabetes, number (%)*
Atrial fibrillation, number (%)*
COPD, number (%)*
Smoking, number (%)
Within the past week
>1 week, number (%)
Never, number (%)
Home medications
Antiplatelets, number (%)*
Warfarin, number (%)*
Statin, number (%)*
Beta-blocker, number (%)*
ACE-inhibitor, number (%)*
Aldosterone antagonist, number (%)
Vitals at presentation
Heart rate, per minute, [mean (SD)]
Systolic blood pressure, mmHg, [mean (SD)]*
Diastolic blood pressure, mmHg, [mean (SD)]
Labs at presentation
Creatinine, mg/dl, [median (IQR)]*
BNP, ng/l, [median (IQR)]*
NT-proBNP, ng/l, [median (IQR)]*
Cardiac troponin I, ng/l, [median (IQR)]*

ACS

Non-ACS cardiovascular

Noncardiac

Chest pain NOS

287 patients (14%)

418 patients (21%)

608 patients (31%)

669 patients (34%)

62 (11)
213 (74)
171 (60)

58 (14)
259 (62)
237 (57)

55 (12)
313 (52)
304 (51)

54 (13)
340 (51)
319 (48)

186 (65)
235 (82)
49 (17)
199 (69)
33 (12)
111 (39)
25 (8.7)
28 (9.8)

176 (42)
297 (71)
112 (27)
240 (57)
53 (13)
104 (25)
66 (16)
46 (11)

170 (28)
395 (65)
76 (13)
284 (47)
45 (7.4)
159 (26)
44 (7.2)
76 (13)

212 (32)
448 (67)
97 (15)
342 (51)
64 (9.6)
195 (29)
58 (8.7)
63 (9.4)

65 (23)
115 (40)
107 (37)

102 (24)
139 (33)
177 (42)

184 (30)
166 (27)
258 (42)

207 (31)
166 (25)
296 (44)

188 (66)
12 (4.2)
169 (59)
158 (55)
155 (54)
2 (0.7)

220 (53)
48 (12)
189 (45)
192 (46)
184 (44)
9 (2.2)

240 (40)
39 (6.4)
220 (36)
210 (35)
215 (35)
8 (1.3)

291 (44)
54 (8.1)
240 (36)
236 (35)
250 (37)
5 (0.7)

80 (18)
146 (28)
81 (17)

82 (24)
146 (31)
82 (19)

82 (18)
140 (26)
79 (15)

80 (17)
141 (24)
80 (15)

1.00 (0.85–1.30)
104 (32–359)
748 (229–3068)
44 (8–254)

1.00 (0.82–1.24)
219 (52–608)
685 (92–2265)
8 (6–26)

0.90 (0.73–1.10)
28 (10–116)
153 (39–463)
6 (6–9)

0.90 (0.75, 1.10)
43 (15, 90)
624 (75, 1910)
6 (6, 9)

ACE, angiotensin-converting enzyme; ACS, acute coronary syndrome; BNP, brain natriuretic peptide; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; IQR, interquartile range; NOS, nothing otherwise specified.
*P value <0.05.
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Fig. 1

Dynamic changes in cTnI and final diagnosis. Patterns of changes in cTnI stratified by final diagnosis. Peak cTnI above the 99th percentile with a
rise/fall means acute cTnI elevation and an elevation without a rise/fall means chronic elevation. Both acute and chronic elevations were observed
in every category. ACS, acute coronary syndrome; cTnI, cardiac troponin I; CV, cardiovascular; NOS, nothing otherwise specified.

cardiovascular and 0% in noncardiac and chest pain NOS,
P < 0.001).
At 180-day follow-up, 45 patients (2.2%) died. Patients
with ACS had the highest mortality followed by nonACS cardiovascular diagnosis (Fig. 2a). cTn elevation was
associated with poor prognosis in every diagnosis, and
the prognostic impact of cTnI was more prominent in
patients with noncardiac diagnosis and chest pain NOS
compared with those with cardiac diagnosis (P for interaction = 0.011; Fig. 3). In Cox analysis, elevated cTnI,
regardless of acute or chronic change, was associated with
higher mortality in all patients (Table 2). This association remained after excluding patients diagnosed with
ACS. When specific final diagnoses were considered, elevated cTnI above the 99th percentile was associated with
higher mortality among patients with UA, CHF, arrhythmia other than atrial fibrillation and ventricular tachycardia, pulmonary embolism, other noncardiac disease and
chest pain NOS (Supplementary Table 2, supplemental
digital content 1, http://links.lww.com/MCA/A485).
MACE at 180-day follow up was observed in 156 patients
(7.8%); ischemic events in 85 (4.2%), AMI in 28 (1.4%),
revascularization in 29 (1.4%), reinfarction in 4 (0.2%),
UA in 34 (1.7%), CHF in 74 (3.7%) and stroke in 10
patients (0.5%). Patients with ACS had the highest incidence of MACE and ischemic events, whereas CHF was
most frequently observed in those with non-ACS cardiovascular disease (Fig. 2b–d). In univariable and multivariable Cox analyses, an elevated cTnI, both acute and

chronic elevation, was associated with a higher incidence
of MACE among all and non-ACS patients (Table 3,
Supplementary Tables 3 and 4, supplemental digital content 1, http://links.lww.com/MCA/A485). Interaction analysis showed the prognostic value of cTnI for MACE was
stronger among patients with non-ACS, especially noncardiac diagnosis and chest pain NOS, and this finding
was also observed with ischemic events and CHF (P for
interaction: <0.001 for MACE, 0.011 for ischemic events
and <0.001 for CHF; Fig. 3). When specific final diagnoses
were considered, elevated cTnI above the 99th percentile
was associated with a higher incidence of MACE among
patients with AMI, UA, CHF, hypertensive crisis, syncope,
aortic stenosis, perimyocarditis, cardiovascular disease
without a specific diagnosis, pneumonia, other noncardiac
disease, noncardiac without specific diagnosis and chest
pain NOS (Supplementary Table 5, supplemental digital
content 1, http://links.lww.com/MCA/A485).

Discussion

In the current study, among patients presenting to ED
with chest pain and possible ACS, cTnI elevation can be
observed even their final diagnosis was not ACS. Elevated
cTn was associated with worse outcomes regardless of
the final diagnosis and no matter whether troponin had
an acute or chronic elevation. Surprisingly, the prognostic value of cTnI was more pronounced in non-ACS than
in ACS patients. These findings highlight the clinical
importance of elevated cTn in patients with chest pain,
irrespective of the final diagnosis of ACS.

Copyright © 2022 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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Fig. 2

(a) Final diagnosis and 180-day mortality. (b) Final diagnosis and 180-day major adverse cardiovascular events. (c) Final diagnosis and 180-day
ischemic events. (d) Final diagnosis and 180-day heart failure events. Patients with ACS had the highest mortality and incidence of MACE and
ischemic events, while CHF was most frequently observed in those with non-ACS cardiovascular disease. ACS, acute coronary syndrome; CHF,
congestive heart failure; CV, cardiovascular, MACE, major adverse cardiovascular events; NOS, not otherwise specified.

One potential explanation for the lower hazard ratio of
cTnI for adverse outcomes in ACS patients in our study
could be appropriate medical and interventional treatments for these patients considering the higher prevalence of coronary angiography, PCI and CABG. This
aggressive up-front care has been shown to decrease
future ACS and MACE [11]. Such treatment pathways
are not as clear in patients with an elevated cTn but
without ACS. In CHOPIN, clinical decisions and adjudication of final diagnoses were made with local study
site troponin assays that may have been older generations and less sensitive than the centaur assay used
in this analysis. Thus, many of the patients diagnosed
with a non-ACS condition may have been diagnosed

with ACS with the adoption of more contemporary
higher sensitivity assays. In the study that evaluated
the implementation of a high sensitivity cTn (hs-cTn)
assay in the 16 Swedish hospitals EDs between 2006
and 2013, patients with chest pain were assessed by
either conventional or hs-cTn assay, and cardiovascular
risk profile and the occurrence of 30-day MACE were
compared [12]. When evaluated with hs-cTn, admitted
patients had a higher cardiovascular risk profile, and
fewer patients experienced MACE. These findings, as
well as results of other studies, suggest hs-cTn, compared with the conventional assay, may improve ED
management and possibly lead to a better prognosis
[2,12–14].
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Fig. 3

Prognostic implication of troponin for mortality and major adverse cardiovascular events. The prognostic impact of cTnI for mortality was higher
among patients with noncardiac diagnosis and chest pain NOS compared to those with ACS and non-ACS CV diagnoses. Similarly, the prognostic value of cTnI for MACE was stronger among patients with non-ACS, especially noncardiac diagnosis and chest pain NOS, and this finding
was also observed with ischemic events and CHF. ACS, acute coronary syndrome; CHF, congestive heart failure; cTnI, cardiac troponin I; CV,
cardiovascular; OR, odds ratio; MACE, major adverse cardiovascular events; NOS, nothing otherwise specified.

Table 2

Cox analysis for 6-month mortality
Univariable

All patients

HR

Log-2 admission cTnI
Admission cTnI above the 99th percentile
cTnI <99th percentile
Acute elevation
Chronic elevation

1.31
6.11
5.67
7.43

1.21–1.41
3.38–11.0
Reference
2.22–14.5
3.90–14.1

P-value
<0.001
<0.001
<0.001
<0.001

Univariable

Non-ACS patients

HR
Log-2 admission cTnI
Admission cTnI above the 99th percentile
cTnI <99th percentile
Acute elevation
Chronic elevation

95% CI

1.43
7.65
4.65
8.23

95% CI
1.28–1.61
3.80–15.4
Reference
1.56–13.9
3.89–17.4

P-value
<0.001
<0.001
0.006
<0.001

ACS, acute coronary syndrome; CAD, coronary artery disease; CI, confidence interval; cTnI, cardiac troponin I; HR, hazard ratio.

The use of a less sensitive local assay may also have led
to undiagnosed type 2 myocardial infarction (T2MI)
and myocardial injury among patients not diagnosed
with ACS. T2MI is prompted by ischemic myocardial
injury from an oxygen supply-demand mismatch secondary to another acute illness [1]. The use of hs-cTn
assays can increase the observed incidence of T2MI
because T2MI associated with lower cTn concentrations

is better detected by higher sensitive assays [6,7,15,16].
Myocardial injury, which is defined as an elevation in
cTnI above the 99th percentile without signs or symptoms of ischemia, is also becoming prevalent in the era
of highly sensitive assays. For now, there is a general
lack of guidance regarding how to investigate, diagnose,
treat and follow up patients with T2MI and myocardial
injury, despite their worse prognoses than type 1 MI

Copyright © 2022 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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Table 3

Cox analysis for 6-month major adverse cardiovascular events
Univariable

All patients

HR

Log-2 admission cTnI
Admission cTnI above the 99th percentile
cTnI <99th percentile
Acute elevation
Chronic elevation

1.23
4.3
4.18
3.71

1.17–1.29
3.12–5.91
Reference
2.59–6.75
2.63–5.24

P-value

Adjusted HR

<0.001
<0.001

1.16
2.65

<0.001
<0.001

2.16
2.54

P-value

Adjusted HR

<0.001
<0.001

1.26
2.94

<0.001
<0.001

2.22
2.74

Univariable

Non-ACS patients
HR
Log-2 admission cTnI
Admission cTnI above the 99th percentile
cTnI <99th percentile
Acute elevation
Chronic elevation

95% CI

Multivariable

1.36
5.56
4.59
4.68

95% CI
1.27–1.46
3.76–8.22
Reference
2.66–7.91
3.00–7.31

95% CI
1.09–1.23
1.90–3.70
Reference
1.31–3.54
1.76–3.65

P-value
<0.001
<0.001
0.002
<0.001

Multivariable
95% CI
1.14–1.39
1.93–4.48
Reference
1.25–3.94
1.70–4.40

P-value
<0.001
<0.001
0.006
<0.001

An acute troponin elevation was defined as a rise or fall of cTnI with at least one value above the 99th percentile. A chronic elevation was defined as a troponin elevation
above the 99th percentile but without a rise/fall.
Factors included in the multivariable model analysis of all patients: age, sex, race, history of CAD, hypertension, heart failure, dyslipidemia, stroke, diabetes, atrial fibrillation, antiplatelets, warfarin, statin, beta-blockers, ACE inhibitors and creatinine.
Analysis of non-ACS patients: age, race, history of CAD, hypertension, heart failure, dyslipidemia, stroke, diabetes, atrial fibrillation, antiplatelets, warfarin, statin,
beta-blockers, ACE inhibitors and creatinine.
ACE, angiotensin-converting enzyme; ACS, acute coronary syndrome; CAD, coronary artery disease; CI, confidence interval; cTnI, cardiac troponin I; HR, hazard ratio.

[5,7,10,15,16]. This lack of clinical guidance may result
in a failure to attenuate the risks associated with cTn
elevation, which may explain the significant relationship
between cTn and poor outcomes in non-ACS patients
in our analysis. Several studies have reported that T2MI
patients with underlying coronary artery disease (CAD)
has a worse prognosis [7,15,17]. However, as shown in
our analysis, investigation for CAD infrequently occurs
in these conditions, resulting in fewer patients undergoing revascularization or receiving medications proven
to improve outcomes in patients with CAD [5,10,15,16].
Further studies are needed to investigate who will benefit from the assessment and treatment for possible underlying CAD among patients with T2MI and myocardial
injury.
Other than myocardial ischemia, cTn can be released
with myocardial injury because of multiple factors
including wall stress from volume overload, left ventricular hypertrophy, neurohormonal activation, inflammation
and altered calcium handling [18]. These pathophysiologic processes are frequently seen in CHF, and elevated
cTn predicts poor prognosis in patients with CHF [19].
Whereas vasodilators may ameliorate cTn release during acute decompensation, this has not been proven to
improve clinical outcomes [20]. There are likely other
risk factors that are not modified in CHF patients with
cTn elevation that may account for the increased risk of
events observed in patients with the final diagnosis of
non-ACS cardiovascular disease.
Among patients with a final diagnosis of noncardiac or
chest pain NOS, an elevated cTnI was observed less
frequently. Nevertheless, given the large proportion of
patients adjudicated with these diagnoses, the absolute

number of patients is large with a substantially heightened
risk of mortality and MACE. A similar finding was shown
in a retrospective study of 48 872 patients presenting with
suspected ACS, but who were discharged without a specific diagnosis. An elevation in cTn above the 99th percentile was observed in 20%, which was associated with
an increased risk of a composite of all-cause mortality,
MI, CHF readmission or stroke [3]. In our analysis, elevated cTnI predicted worse outcomes in patients with
HF, hypertensive crisis, syncope, arrhythmia, aortic stenosis, perimyocarditis and pulmonary embolism. In these
patients, higher cTnI can be associated with more severe
myocardial damage with underlying cardiovascular conditions and, thus, predicted poor prognosis [17,21]. However,
other than patients with final diagnoses of cardiovascular
diseases, worse outcomes with cTnI elevation mainly arise
from undefined final diagnoses such as other noncardiac
diagnoses, noncardiac without a specific diagnosis and
chest pain NOS. Therefore, in these patients, the causes of
cTnI elevation and its rationale for predicting worse outcomes remain uncertain. One possible explanation is undiagnosed, or misdiagnosed ACS and cardiovascular diseases
were included in these patients, and risks associated with
MI or myocardial injury were not appropriately treated.
In the current analysis, among patients with noncardiac
diagnosis and chest pain NOS, only about one-third of
patients were assessed for underlying CAD by stress testing, and coronary angiography was performed in less than
10%. The implementation of newer Tn assays may promote assessment for hidden CAD and potentially improve
their clinical outcomes [2,12–14]. Thus, our findings and
those of other studies emphasize that excluding ACS and
having an undetermined final diagnosis do not indicate a
low-risk patient population. Further research is required to
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investigate the mechanism behind cTn elevation and how
to assess, risk stratify and manage patients with undetermined cause of cTn elevation.

Limitation

The CHOPIN study enrolled a specific population of
patients presenting with symptoms concerning for ACS;
thus, findings of this study may not be applicable to other
populations. Although the final diagnosis was adjudicated
by at least two cardiologists independently, misclassification may occur since they were blinded to the results of
the more sensitive cTnI assay used in this analysis. The
cTnI assay used in this study was contemporary when the
CHOPIN study was conducted, but the current guidelines recommend hs-cTn measurements over less sensitive older assays [22]. As newer assays can detect more
cases of MI and myocardial injury, this may have affected
final diagnosis adjudication and the results of our analysis.
A detailed assessment of renal function was lacking, such
as subgroup analysis according to the levels of glomerular
filtration rate. The follow-up period was relatively short
(6 months), and a longer follow-up is lacking. Because of
the small number of deaths, multivariate analysis was not
applied for the mortality endpoint. The study is a post
hoc analysis of prospective cohort; thus, the result is only
hypothesis-generating, and the influence of unmeasured
confounding factors needs to be considered in the multivariable analysis. Despite multiple adjustments in the
Cox regression analysis for MACE, residual confounder
may influence the result.

Conclusion

Among patients presenting to the ED with chest pain,
higher concentrations of cTnI were associated with
increased mortality and MACE, even in non-ACS
patients. Importantly, the prognostic value of cTnI was
more pronounced in non-ACS patients than in ACS
patients. Further study is needed to determine causes
of elevated cTn in patients without ACS and develop
treatment pathways to reduce risk of mortality and
MACE.
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